Anterogen.Co.,Ltd. (KOSDAQ:065660)

Market Cap	391.24B +105.1%
Revenue (ttm)	7.32B +5.3%
Net Income	-1.91B
EPS	-193.30
Shares Out	10.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,458
Average Volume	44,974
Open	39,750
Previous Close	40,100
Day's Range	37,000 - 39,900
52-Week Range	16,510 - 51,000
Beta	0.33
RSI	46.00
Earnings Date	n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 065660

Financial Performance

In 2024, Anterogen.Co.,Ltd.'s revenue was 6.93 billion, an increase of 6.66% compared to the previous year's 6.50 billion. Losses were -2.29 billion, -19.29% less than in 2023.